Kaur Balpreet, Malik Sonia, Prakash Ved, Bhatia Vandana, Gupta Deepu
Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, Bathinda, Punjab, India.
Southend Fertility & IVF, New Delhi, India.
J Family Reprod Health. 2023 Mar;17(1):45-53. doi: 10.18502/jfrh.v17i1.11977.
Achieving pregnancy in poor ovarian response patients is a challenge. Failed fertilization after ICSI, despite normal semen parameters is due to defects in oocyte activation. In-vitro activation of oocytes using Ca agents can be useful in increasing the fertilization rates in these patients. This study aimed to evaluate the efficacy of artificial oocyte activation by calcium ionophores in poor responders in improving fertilization, cleavage, implantation and clinical pregnancy rates.
This is a prospective, cohort study conducted on 120 patients having poor ovarian response, (POSEIDON criteria) undergoing in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment at Southend Fertility and IVF, New Delhi from 1 August 2019 to 31 March 2020. Exclusion criterion was patients with partners with abnormal semen parameters. After OPU patients were randomized into two groups, study group (n=50) underwent ICSI-AOA (ICSI followed by artificial oocyte activation) using calcium ionophore- GM508 Cult-Active Solution) while the controls (n=57) were subjected to ICSI only.
Comparison of ICSI-AOA and ICSI groups showed: (i) number of fertilized oocytes - 2.42 vs. 2.16, p = 0.049 (ii) No. of cleavage stage embryos 2.32 vs. 1.96, p = 0.008 (iii) No. of grade A embryos 1.52 vs. 1.04, p = 0.009 (iv) fertilization rate - 89.00% vs. 83.04%, p = 0.093 (v) cleavage rate - 96.33% vs. 92.55%, p = 0.165 (vi) implantation rate - 27.14% vs. 11.74%, p = 0.098 (vii) clinical pregnancy rate - 34.3% vs. 20.5%, p = 0.167.
The number of fertilized oocytes, grade A embryos and cleavage stage embryos formed after ICSI-AOA were statistically significantly more than ICSI. ICSI-AOA has not shown improvement in fertilization, cleavage, implantation and clinical pregnancy rate. From the present study the conclusive evidence cannot be drawn due to small sample size hence further studies are needed on a larger population.
使卵巢反应不良患者成功受孕是一项挑战。尽管精液参数正常,但卵胞浆内单精子注射(ICSI)后受精失败是由于卵母细胞激活缺陷所致。使用钙制剂对卵母细胞进行体外激活可能有助于提高这些患者的受精率。本研究旨在评估钙离子载体人工激活卵母细胞对卵巢反应不良患者受精、卵裂、着床及临床妊娠率的改善效果。
这是一项前瞻性队列研究,对2019年8月1日至2020年3月31日在新德里绍森德生育与体外受精中心接受体外受精/卵胞浆内单精子注射(IVF/ICSI)治疗的120例卵巢反应不良患者(POSEIDON标准)进行研究。排除标准为配偶精液参数异常的患者。卵母细胞采集(OPU)后,患者被随机分为两组,研究组(n = 50)采用钙离子载体GM508培养活性溶液进行ICSI - AOA(ICSI后进行人工卵母细胞激活),而对照组(n = 57)仅接受ICSI。
ICSI - AOA组与ICSI组比较显示:(i)受精卵母细胞数 - 2.42对2.16,p = 0.049;(ii)卵裂期胚胎数2.32对1.96,p = 0.008;(iii)A级胚胎数1.52对1.04,p = 0.009;(iv)受精率 - 89.00%对83.04%,p = 0.093;(v)卵裂率 - 96.33%对92.55%,p = 0.165;(vi)着床率 - 27.14%对11.74%,p = 0.098;(vii)临床妊娠率 - 34.3%对20.5%,p = 0.167。
ICSI - AOA后形成的受精卵母细胞、A级胚胎和卵裂期胚胎数量在统计学上显著多于ICSI组。ICSI - AOA在受精、卵裂、着床及临床妊娠率方面未显示出改善。由于样本量小,本研究无法得出确凿证据,因此需要对更大规模人群进行进一步研究。